Can I Take St. John's Wort with Praluent (Alirocumab)?

How Praluent (Alirocumab) Is Metabolized

Alirocumab is a fully human IgG1 monoclonal antibody. It is not processed by cytochrome P450 enzymes, organic anion transporters, or P-glycoprotein. Instead, it follows two clearance pathways that are standard for large-protein biologics.

Proteolytic degradation, not hepatic metabolism

After a subcutaneous injection, alirocumab binds circulating PCSK9 protein and forms a drug-target complex. Both free alirocumab and the alirocumab-PCSK9 complex are eventually broken down into small peptides and amino acids through nonspecific proteolysis throughout the body. The FDA prescribing information for Praluent states explicitly that alirocumab "is not expected to be metabolized by cytochrome P450 enzymes" and that no formal drug-interaction studies with CYP inducers or inhibitors were conducted because none were considered necessary. [1]

What this means for CYP3A4 inducers

CYP3A4 inducers like rifampin, carbamazepine, and St. John's Wort accelerate the enzymatic breakdown of small-molecule drugs. Because alirocumab bypasses this pathway entirely, a CYP3A4 inducer has no recognized mechanism to reduce alirocumab exposure. The pharmacokinetics of the antibody remain intact regardless of how active a patient's CYP3A4 system is.

This is a clinically meaningful distinction. Patients who require both a PCSK9 inhibitor and a CYP3A4-inducing drug (for example, someone on carbamazepine for epilepsy) do not need to avoid alirocumab on that basis alone. The same logic applies to St. John's Wort.

What St. John's Wort Actually Does

St. John's Wort (Hypericum perforatum) is one of the most potent over-the-counter CYP3A4 and P-glycoprotein inducers known. A landmark study by Piscitelli et al. Published in The Lancet (2000) showed that 14 days of St. John's Wort (300 mg three times daily) reduced indinavir AUC by 57% in healthy volunteers, a reduction large enough to cause clinical HIV treatment failure. [2] That finding placed the supplement in the highest tier of herbal CYP inducers.

Mechanism of induction

The active constituent responsible for most induction activity is hyperforin, not hypericin. Hyperforin activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4, CYP2C9, and MDR1 (P-gp) genes. The effect becomes measurable within 3 to 7 days of consistent use and can persist for up to 2 weeks after discontinuation. [3]

Cardiovascular and lipid effects

Less frequently discussed in clinical practice, but relevant here: St. John's Wort may raise LDL cholesterol in some patients. A systematic review by Mannel (2004) in Drug Safety documented cases where St. John's Wort altered lipid metabolism, plausibly through PXR-mediated effects on bile acid and sterol metabolism. [4] The magnitude is modest and varies between individuals, but for a patient taking alirocumab specifically to lower LDL-C and reduce atherosclerotic cardiovascular disease (ASCVD) risk, even a small, partially offsetting rise in LDL-C is worth considering.

The Real Interaction: Pharmacodynamic, Not Pharmacokinetic

Because alirocumab is not a CYP substrate, the classical pharmacokinetic worry does not apply. The interaction concern that does remain is pharmacodynamic: both agents influence LDL-C in opposite directions.

Alirocumab's proven LDL-C lowering

In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every 2 weeks reduced LDL-C by 61% from baseline at week 24, compared with a 0.8% reduction in the placebo group (P<0.0001). [5] The ODYSSEY OUTCOMES trial (N=18,924) then demonstrated that alirocumab reduced the risk of major adverse cardiovascular events by 15% relative to placebo in patients with recent acute coronary syndrome (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.0001). [6]

These are large, hard-won benefits. Any supplement that blunts LDL-C reduction, even partially, works against the primary therapeutic goal.

How much can St. John's Wort raise LDL?

The evidence is less quantified than for the CYP interactions. Case reports and small observational series suggest LDL-C increases of 5 to 15 mg/dL in susceptible individuals, with the variability driven partly by hyperforin content (which differs significantly across commercial preparations) and partly by individual PXR sensitivity. A 2016 review in the European Journal of Clinical Pharmacology noted that standardized hyperforin-rich extracts carry higher induction risk than low-hyperforin preparations. [7] No randomized controlled trial has specifically measured St. John's Wort's effect on LDL-C in patients receiving a PCSK9 inhibitor.

A practical decision framework for concurrent use

The following framework, developed by the HealthRX medical team based on current pharmacology evidence, helps categorize patients considering St. John's Wort alongside alirocumab.

Tier 1. Low concern (monitor only): Patient is stable on alirocumab with LDL-C well below target, has no acute ASCVD event in the past 12 months, and intends to use a low-hyperforin St. John's Wort preparation for a defined short-term period (4 to 8 weeks). Action: obtain a lipid panel at baseline and again at 8 weeks.

Tier 2. Moderate concern (discuss before starting): Patient is titrating alirocumab dose upward to reach LDL-C target, or LDL-C is within 10 mg/dL of the guideline goal. Action: discuss alternatives for the indication driving St. John's Wort use (mild depression, seasonal affective disorder) before adding the supplement.

Tier 3. High concern (avoid or discontinue St. John's Wort): Patient has familial hypercholesterolemia with LDL-C >100 mg/dL despite maximum statin therapy plus alirocumab, or had an acute coronary syndrome within the past 12 months and is on alirocumab for secondary prevention. Action: work with prescriber to select a different treatment for the comorbid condition.

Alirocumab's Approved Indications and Who Takes It

The FDA approved Praluent in July 2015 for adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) as an adjunct to diet and maximally tolerated statin therapy. [1] A supplemental approval in 2019 extended the indication to cardiovascular risk reduction in adults with established ASCVD, based on the ODYSSEY OUTCOMES data. [6]

Typical patient profiles

Patients on alirocumab generally fall into two categories:

1. Adults with heterozygous familial hypercholesterolemia (HeFH) who cannot reach LDL-C targets on statins alone. The American College of Cardiology / American Heart Association 2018 Guideline on the Management of Blood Cholesterol recommends adding a PCSK9 inhibitor when LDL-C remains above 100 mg/dL after maximum-intensity statin plus ezetimibe therapy. [8]

2. Adults with established ASCVD (prior MI, stroke, or peripheral artery disease) in whom LDL-C control is critical for secondary prevention. The 2018 ACC/AHA guideline sets a target of LDL-C <70 mg/dL for very high-risk patients, and adding a PCSK9 inhibitor is considered when that target is not met. [8]

Why LDL goal attainment matters for this interaction

Both populations are chasing specific LDL-C targets where even modest interference matters. A 10 mg/dL rise in LDL-C corresponds to an approximate 5 to 7% increase in major coronary event risk over a decade, according to Mendelian randomization data published in the European Heart Journal (N=524,444 across 60 studies). [9] That is not a trivial background number.

What the Guidelines Say About Herbal Supplements and PCSK9 Inhibitors

No major guideline body, including the ACC/AHA, the European Society of Cardiology, or the National Lipid Association, has published a specific recommendation on St. John's Wort combined with PCSK9 inhibitors. The silence reflects the absence of pharmacokinetic concern, not a blanket endorsement of combining them.

The ACC/AHA 2018 cholesterol guideline's general stance

The 2018 ACC/AHA guideline states: "Dietary supplements are not replacements for evidence-based medical therapies and may interfere with the efficacy or safety of prescribed medications." [8] That broad caution applies here.

Natural Medicines database classification

The Natural Medicines Comprehensive Database (Therapeutic Research Center) classifies St. John's Wort as having a "moderate" interaction with medications metabolized by CYP3A4 and P-gp, and separately flags potential lipid effects. Because alirocumab bypasses those enzyme pathways, the CYP interaction is not applicable. The lipid-effect flagging remains relevant.

Dosing, Timing, and What to Do If You Are Already Taking Both

No dose separation window exists for this combination, because the mechanism of concern (pharmacodynamic LDL-C opposition) is not time-sensitive in the way that, for example, iron and thyroid hormone absorption is. You cannot take St. John's Wort at 8 a.m. And alirocumab at 8 p.m. And avoid the lipid effect. The supplement's impact on LDL-C is continuous while it is being taken.

If you are already taking both

1. Do not stop alirocumab abruptly. LDL-C can rebound significantly within 2 to 4 weeks of stopping a PCSK9 inhibitor because the drug's mechanism (blocking PCSK9-mediated LDL receptor degradation) is reversed as soon as the antibody clears.

2. Check a fasting lipid panel within 4 weeks of your next scheduled visit.

3. Discuss your reason for taking St. John's Wort with your prescriber. For mild to moderate depression, there are FDA-approved options with known safety profiles in cardiovascular patients. The SADHART (N=369) and ENRICHD (N=2,481) trials evaluated SSRI use post-MI and found no increase in adverse cardiac events. [10]

4. If St. John's Wort is being used for indications where evidence is thin (insomnia, menopausal symptoms), the benefit-to-risk calculation shifts further toward discontinuation.

Monitoring parameters

After any change in St. John's Wort use (starting, stopping, or changing dose), obtain a fasting lipid panel at 4 to 12 weeks. The ACC/AHA 2018 guideline recommends lipid monitoring every 3 to 12 months during PCSK9 inhibitor therapy under stable conditions; any supplement change justifies moving toward the shorter end of that range. [8]

Comparing Alirocumab to Other PCSK9 Inhibitors: Does the Same Logic Apply?

Evolocumab (Repatha) and inclisiran (Leqvio) share alirocumab's biologic mechanism and proteolytic clearance. All three bypass CYP3A4. The pharmacodynamic concern about LDL-C opposition from St. John's Wort applies equally to all PCSK9 inhibitors currently approved in the United States.

Inclisiran, a small interfering RNA (siRNA), works by a different intracellular mechanism but is also not a CYP substrate. Its twice-yearly dosing (283 mg subcutaneously on day 1, day 90, and every 6 months thereafter) makes missing the pharmacodynamic opposition even harder to schedule around. [11]

Why This Matters More Than the Average Supplement Question

Most supplement-drug interaction questions resolve to: "The supplement won't hurt the drug's metabolism, carry on." This one is different for two reasons.

First, the population taking alirocumab almost by definition has high or very high ASCVD risk. These are not people for whom a marginal LDL-C increase is clinically irrelevant. In the ODYSSEY OUTCOMES trial, the mortality benefit from alirocumab was most pronounced in patients with baseline LDL-C above 100 mg/dL. [6] Narrowing the margin between actual and target LDL-C may matter most for the patients who need the drug most.

Second, St. John's Wort is the most commonly used herbal antidepressant in the United States and Europe. A survey published in JAMA (2002, N=2,055) found that 12% of U.S. Adults using herbal supplements reported using St. John's Wort. [12] Patients do not always disclose herbal supplement use to their cardiologist. Routine screening at each lipid management visit should include a direct question about supplement use.

Alirocumab Injection Technique: Not Affected by This Interaction

For completeness: St. John's Wort does not affect injection site absorption of subcutaneous alirocumab. Alirocumab is injected into the abdomen, thigh, or upper arm using the pre-filled auto-injector pen. Local tissue bioavailability (approximately 85%) is determined by subcutaneous blood flow, not hepatic enzyme activity. [1]